BV2 JOINS SNC-LAVALIN IN EUROPE
SNC-Lavalin*** is pleased to announce that BV2, a key player in pharmaceutical and biotechnology engineering in the Benelux countries, is joining SNC-Lavalin in Europe**. This Belgian firm, headquartered in Onze-Lieve-Vrouw-Waver, near Mechelen, north of Brussels, has 63 employees.
BV2 clients include prominent companies in the pharmaceutical, biotechnology and cosmetics industries, such as GlaxoSmithKline, J & J, Pfizer, Alcon, Galapagos Mechelen & Leiden, Tropisch Instituut Prins Leopold, Mylène Heist o/d Berg, Eurogentec Luik and Henogen Seneffe.
By joining SNC-Lavalin, an international leader in engineering and construction, and particularly SNC-Lavalin Pharma*, its subsidiary specializing in fine chemicals and pharmaceutical and biotechnology products, BV2 can now rely on an international network of 800 pharmaceutical and biotechnology industry experts, including 240 in Europe, and be part of a specialized group of European and international centres of competence. Through this acquisition, SNC Lavalin Pharma is consolidating its presence in the Benelux countries.
“BV2 has all of the skills to provide our clients with a full range of services, from design to commissioning to certification of their facilities,” said Jean Claude Pingat, President of SNC-Lavalin in Europe.
“Through the SNC Lavalin Pharma network, BV2 can now provide its clients with support in their international projects.”, said BV2 executives Luc Verborgt and Jan Verschoren. “We are proud to be joining SNC Lavalin Pharma, one of the major leaders in providing pharmaceutical and biotechnology engineering services.”
*SNC-Lavalin Pharma currently has 800 skilled employees in its specialized operations in Canada, the United States, France, Belgium, Spain and India, and in the other SNC Lavalin offices around the world. The contact information for the BV2 offices in Wavre, Belgium, is the following: Dorp 38 B-2861, Onze-Lieve-Vrouw-Waver; Tel: +3215768870.
**SNC-Lavalin in Europe (2,200 employees; total sales 347 million euros in 2007) is active in four main areas of construction engineering: buildings and development; infrastructure, transportation and environment; industrial processes; and life sciences (SNC-Lavalin Pharma/SNC-Lavalin Agro). Its teams in about 60 facilities manage public and private sector projects from the strategic assessment phase through to the commissioning phase.
***SNC-Lavalin in Europe is a subsidiary of SNC-Lavalin (TSX: SNC), one of the largest engineering and construction groups in the world and a major player in infrastructure ownership and operations and maintenance services. SNC Lavalin has a workforce of more than 20,000 employees around the world (September 2008), and in 2007 generated sales of 4.6 billion euros. www.snclavalin.com
– 30 –
Media ContactAnne Fiaschi
Vice-President, Public Relations and Communications, Europe
SNC-Lavalin Europe S.A.S.
InvestorsJean Claude Pingat
SNC-Lavalin Group Inc.
SNC-Lavalin in Europe